Cizman Ziga, Isaacson Ari, Burke Charles
Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Department of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
J Vasc Interv Radiol. 2016 Oct;27(10):1487-1493.e1. doi: 10.1016/j.jvir.2016.04.015. Epub 2016 Jun 24.
To review the available safety and efficacy data for prostatic artery embolization (PAE) in the treatment of benign prostatic hyperplasia (BPH).
PubMed was searched for publications that included PAE for the treatment of BPH through May 2015. Two independent reviewers determined the appropriateness for inclusion of each article and compiled data by using pooled weighted means and standard deviations.
The literature search identified 161 articles, of which 7 studies, with a total of 562 patients, met all inclusion/exclusion criteria. PAEs were performed bilaterally in 85% of patients, unilaterally in 12%, and unsuccessfully in 3%. International Prostate Symptom Score decreased from 24.51 ± 6.12 at baseline to 10.42 ± 5.39 at 6 months. Quality of life score decreased from 4.76 ± 0.98 at baseline to 2.51 ± 1.13 at 6 months. Peak urinary flow rate increased from 8.41 mL/s ± 2.63 at baseline to 15.44 mL/s ± 5.64 at 6 months. Postvoid residual measurement decreased from 105.94 mL ± 76.77 at baseline to 39.57 mL ± 15 at 6 months. Prostate-specific antigen level decreased from 4.79 ng/mL ± 5.42 at baseline to 3.16 ng/mL ± 1.5 at 6 months. None of these parameters showed clinically significant changes from 6 months to 12 months. Total prostate volume decreased from 96.56 cm3 ± 35.47 at baseline to 46.73 cm3 ± 20.51 at 12 months. There were 200 minor complications and 1 major complication.
PAE improves lower urinary tract symptoms caused by BPH, with a favorable short- to midterm safety profile.
回顾前列腺动脉栓塞术（PAE）治疗良性前列腺增生（BPH）的现有安全性和有效性数据。
检索PubMed截至2015年5月收录的有关PAE治疗BPH的文献。两名独立审阅者确定每篇文章是否适合纳入研究，并使用合并加权均值和标准差汇总数据。
文献检索共识别出161篇文章，其中7项研究共562例患者符合所有纳入/排除标准。85%的患者双侧进行PAE，12%的患者单侧进行，3%的患者手术失败。国际前列腺症状评分从基线时的24.51±6.12降至6个月时的10.42±5.39。生活质量评分从基线时的4.76±0.98降至6个月时的2.51±1.13。最大尿流率从基线时的8.41 mL/s±2.63增至6个月时的15.44 mL/s±5.64。残余尿量从基线时的105.94 mL±76.77降至6个月时的39.57 mL±15。前列腺特异性抗原水平从基线时的4.79 ng/mL±5.42降至6个月时的3.16 ng/mL±1.5。从6个月到12个月，这些参数均未显示出临床显著变化。前列腺总体积从基线时的96.56 cm³±35.47降至12个月时的46.73 cm³±20.51。发生200例轻微并发症和1例严重并发症。
PAE可改善BPH引起的下尿路症状，具有良好的中短期安全性。
